{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:22:42Z","timestamp":1785208962630,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-025-00258-4","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:02:48Z","timestamp":1754258568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Function of 18F-FDG PET\/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2016-3552","authenticated-orcid":false,"given":"Cl\u00e9mence M. C.","family":"Huigen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Latifyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-0611","authenticated-orcid":false,"given":"Marie","family":"Nicod Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-7696","authenticated-orcid":false,"given":"Niklaus","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-5985","authenticated-orcid":false,"given":"Daniel","family":"Abler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-0304","authenticated-orcid":false,"given":"Adrien","family":"Depeursinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-1374","authenticated-orcid":false,"given":"John O.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-150X","authenticated-orcid":false,"given":"Mario","family":"Jreige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"1","key":"258_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41747-023-00326-z","volume":"7","author":"D Abler","year":"2023","unstructured":"Abler D, Schaer R, Oreiller V, Verma H, Reichenbach J, Aidonopoulos O et al (2023) QuantImage v2: a comprehensive and integrated physician-centered cloud platform for radiomics and machine learning research. Eur Radiol Exp 7(1):16","journal-title":"Eur Radiol Exp"},{"issue":"3","key":"258_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.116.180729","volume":"58","author":"SS Ahn","year":"2017","unstructured":"Ahn SS, Hwang SH, Jung SM, Lee S-W, Park Y-B, Yun M, Song JJ (2017) Evaluation of spleen glucose metabolism using 18F-FDG PET\/CT in patients with febrile autoimmune disease. J Nucl Med 58(3):507\u2013513","journal-title":"J Nucl Med"},{"issue":"4","key":"258_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.4049\/jimmunol.0803404","volume":"182","author":"ZM Bamboat","year":"2009","unstructured":"Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP et al (2009) Human liver dendritic cells promote T cell hyporesponsiveness. J Immunol 182(4):1901\u20131911","journal-title":"J Immunol"},{"key":"258_CR4","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1102\/1470-7330.2007.9012","volume":"7","author":"M Benamor","year":"2007","unstructured":"Benamor M, Ollivier L, Brisse H, Moulin-Romsee G, Servois V, Neuenschwander S (2007) PET\/CT imaging: what radiologists need to know. Cancer Imaging 7:S95\u2013S99","journal-title":"Cancer Imaging"},{"issue":"2","key":"258_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","volume":"15","author":"M Biewenga","year":"2021","unstructured":"Biewenga M, van der Kooij MK, Wouters M, Aarts MJB, van den Berkmortel F, de Groot JWB et al (2021) Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol Int 15(2):510\u2013519","journal-title":"Hepatol Int"},{"issue":"7","key":"258_CR6","doi-asserted-by":"publisher","first-page":"e0270950","DOI":"10.1371\/journal.pone.0270950","volume":"17","author":"F Castagnoli","year":"2022","unstructured":"Castagnoli F, Doran S, Lunn J, Minchom A, O\u2019Brien M, Popat S et al (2022) Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. PLoS ONE 17(7):e0270950","journal-title":"PLoS ONE"},{"issue":"10","key":"258_CR7","doi-asserted-by":"publisher","first-page":"e005635","DOI":"10.1136\/jitc-2022-005635","volume":"10","author":"A Coukos","year":"2022","unstructured":"Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S et al (2022) Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. J Immunother Cancer 10(10):e005635","journal-title":"J Immunother Cancer"},{"issue":"1","key":"258_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","volume":"79","author":"M Cunningham","year":"2024","unstructured":"Cunningham M, Gupta R, Butler M (2024) Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology 79(1):198\u2013212","journal-title":"Hepatology"},{"issue":"6","key":"258_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68(6):1181\u20131190","journal-title":"J Hepatol"},{"issue":"12","key":"258_CR10","first-page":"6129","volume":"28","author":"M Dougan","year":"2020","unstructured":"Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P et al (2020) Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 28(12):6129\u20136143","journal-title":"Support Care Cancer"},{"issue":"1","key":"258_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jmrs.662","volume":"70","author":"M Elmahdy","year":"2023","unstructured":"Elmahdy M, Sebro R (2023) Radiomics analysis in medical imaging research. J Med Radiat Sci 70(1):3\u20137","journal-title":"J Med Radiat Sci"},{"issue":"20","key":"258_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"6","key":"258_CR13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s12072-023-10539-4","volume":"17","author":"H Fu","year":"2023","unstructured":"Fu H, Shen Z, Lai R, Zhou T, Huang Y, Zhao S et al (2023) Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury. Hepatol Int 17(6):1626\u20131636","journal-title":"Hepatol Int"},{"issue":"2","key":"258_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.15403\/jgld-3508","volume":"30","author":"K Gabora","year":"2021","unstructured":"Gabora K, Piciu A, Piciu D (2021) Drug induced liver injury to immune checkpoint inhibitors detected by F18-fluorodeoxyglucose PET\/CT. J Gastrointestin Liver Dis 30(2):191","journal-title":"J Gastrointestin Liver Dis"},{"issue":"12","key":"258_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238","journal-title":"Ann Oncol"},{"issue":"3","key":"258_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bj\u00f6rnsson ES (2019) Drug-induced liver injury\u2014types and phenotypes. N Engl J Med 381(3):264\u2013273","journal-title":"N Engl J Med"},{"issue":"6","key":"258_CR17","doi-asserted-by":"publisher","first-page":"100719","DOI":"10.1016\/j.jhepr.2023.100719","volume":"5","author":"L Hountondji","year":"2023","unstructured":"Hountondji L, Ferreira De Matos C, Leboss\u00e9 F, Quantin X, Lesage C, Palassin P et al (2023) Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 5(6):100719","journal-title":"JHEP Rep."},{"issue":"4","key":"258_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19(4):254\u2013267","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"258_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R (2018) Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J Clin Pathol 71(8):665\u2013671","journal-title":"J Clin Pathol"},{"issue":"1","key":"258_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-019-0551-y","volume":"7","author":"KM Knudson","year":"2019","unstructured":"Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR (2019) Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer 7(1):82","journal-title":"J Immunother Cancer"},{"issue":"1","key":"258_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13244-023-01415-8","volume":"14","author":"B Kocak","year":"2023","unstructured":"Kocak B, Baessler B, Bakas S, Cuocolo R, Fedorov A, Maier-Hein L et al (2023) CheckList for EvaluAtion of Radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII. Insights Imaging 14(1):75","journal-title":"Insights Imaging"},{"key":"258_CR22","doi-asserted-by":"crossref","unstructured":"Kubota K, Ogawa M, Ji B, Watabe T, Zhang MR, Suzuki H et al (2019) Basic science of PET imaging for inflammatory diseases. PET\/CT for Inflammatory Diseases, pp 1\u201342","DOI":"10.1007\/978-981-15-0810-3_1"},{"issue":"33","key":"258_CR23","doi-asserted-by":"publisher","first-page":"eaau6085","DOI":"10.1126\/sciimmunol.aau6085","volume":"4","author":"SM Lewis","year":"2019","unstructured":"Lewis SM, Williams A, Eisenbarth SC (2019) Structure and function of the immune system in the spleen. Sci Immunol 4(33):eaau6085","journal-title":"Sci Immunol"},{"key":"258_CR24","doi-asserted-by":"publisher","first-page":"8694397","DOI":"10.1155\/2018\/8694397","volume":"2018","author":"JE Markel","year":"2018","unstructured":"Markel JE, Noore J, Emery EJ, Bobnar HJ, Kleinerman ES, Lindsey BA (2018) Using the spleen as an in vivo systemic immune barometer alongside osteosarcoma disease progression and immunotherapy with \u03b1-PD-L1. Sarcoma 2018:8694397","journal-title":"Sarcoma"},{"issue":"9","key":"258_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"258_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41416-021-01375-0","volume":"125","author":"W Mu","year":"2021","unstructured":"Mu W, Katsoulakis E, Whelan CJ, Gage KL, Schabath MB, Gillies RJ (2021) Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors. Br J Cancer 125(2):229\u2013239","journal-title":"Br J Cancer"},{"issue":"4","key":"258_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"258_CR28","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","volume":"11","author":"L Shojaie","year":"2021","unstructured":"Shojaie L, Ali M, Iorga A, Dara L (2021) Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B 11(12):3727\u20133739","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"258_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jcag\/gwab019","volume":"5","author":"MK Smith","year":"2022","unstructured":"Smith MK, Chan Y, Suo AE, Shaheen AA, Congly SE, Tandon P et al (2022) Clinical course and treatment implications of combination immune checkpoint inhibitor-mediated hepatitis: a multicentre cohort. J Can Assoc Gastroenterol 5(1):39\u201347","journal-title":"J Can Assoc Gastroenterol"},{"key":"258_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"258_CR31","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77(21):e104\u2013e107","journal-title":"Cancer Res"},{"key":"258_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/978-90-368-2449-1","volume-title":"Leerboek oncologie","author":"JHJM van Krieken","year":"2020","unstructured":"van Krieken JHJM, Beets-Tan RGH, Olofsen MJJ, Rutten HJT (2020) Leerboek oncologie. Bohn Stafleu van Loghum, Houten"},{"issue":"1","key":"258_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13244-020-00887-2","volume":"11","author":"JE van Timmeren","year":"2020","unstructured":"van Timmeren JE, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B (2020) Radiomics in medical imaging-\"how-to\" guide and critical reflection. Insights Imaging 11(1):91","journal-title":"Insights Imaging"},{"issue":"1","key":"258_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM (2023) Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. Npj Precis Oncol 7(1):41","journal-title":"Npj Precis Oncol"},{"issue":"9","key":"258_CR35","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1111\/liv.14555","volume":"40","author":"J Wei","year":"2020","unstructured":"Wei J, Jiang H, Gu D, Niu M, Fu F, Han Y et al (2020) Radiomics in liver diseases: current progress and future opportunities. Liver Int 40(9):2050\u20132063","journal-title":"Liver Int"},{"issue":"1","key":"258_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13075-015-0542-4","volume":"17","author":"Z Yang","year":"2015","unstructured":"Yang Z, Matteson EL, Goronzy JJ, Weyand CM (2015) T-cell metabolism in autoimmune disease. Arthritis Res Ther 17(1):29","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"258_CR37","first-page":"103","volume":"17","author":"W Zam","year":"2022","unstructured":"Zam W, Ali L (2022) Immune Checkpoint Inhibitors in the Treatment of Cancer. Curr Rev Clin Exp Pharmacol 17(2):103\u2013113","journal-title":"Curr Rev Clin Exp Pharmacol"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00258-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-025-00258-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00258-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:20:10Z","timestamp":1757251210000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-025-00258-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1186\/s41824-025-00258-4","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the local Ethics Research Committee of the State of Vaud (approval number CER-VD #2018-01513). All patients participating in this study had signed an institutional general informed consent form for the retrospective use of their data in clinical research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}